The footprints of cancer development: Cancer biomarkers

被引：101

作者：

Ullah, Mohd. Fahad ^{[1
]}

Aatif, Mohammad ^{[1
]}

机构：

[1] Aligarh Muslim Univ, Fac Life Sci, Dept Biochem, Aligarh 202002, Uttar Pradesh, India

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 03期

关键词：

Biomarkers; Diagnosis; Proteomics; Cancer; Microarray profile; PROSTATE-SPECIFIC ANTIGEN; MESSENGER-RNA EXPRESSION; TUMOR-SUPPRESSOR GENE; PLASMINOGEN-ACTIVATOR SYSTEM; HUMAN TISSUE KALLIKREINS; METHYLACYL-COA RACEMASE; MICRORNA EXPRESSION; PROMOTER HYPERMETHYLATION; DIFFERENTIAL EXPRESSION; CYSTEINE CATHEPSINS;

D O I：

10.1016/j.ctrv.2008.10.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diagnostic detection and measurement of cancer disease progression are essential elements for successful cancer disease management. The early stages of cancer development carry the maximum potential for therapeutic interventions. However, these stages are often asymptomatic, leading to delayed diagnosis at the very advanced stages when effective treatments are unavailing. The application of biomarkers to cancer is leading the way because of the unique association of genomic changes in cancer cells with the disease process. They have the potential to not only help identify who will develop cancer but also to predict as to when the event is most likely to occur. In recent years, there has been an enormous effort to develop specific and sensitive biomarkers for precise and accurate screening, diagnosis, prognosis and monitoring of high risk cancer to assist with therapeutic decisions. The present article is a brief review of the emerging trends in the development of biomarkers for early detection and precise evaluation of cancer disease. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：193 / 200

页数：8

共 148 条

[101]

PALMERTOY DE, 2002, TUMOR MARKERS PHYSL, P391

[102] Detection and clinical importance of micrometastatic disease [J].

Pantel, K ;

Cote, RJ ;

Fodstad, O .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (13) :1113-1124

[103] Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis [J].

Partin, AW ;

Catalona, WJ ;

Finlay, JA ;

Darte, C ;

Tindall, DJ ;

Young, CYF ;

Klee, GG ;

Chan, DW ;

Rittenhouse, HG ;

Wolfert, RL ;

Woodrum, DL .

UROLOGY, 1999, 54 (05) :839-845

[104]

Pelosi G, 1997, J PATHOL, V183, P62, DOI 10.1002/(SICI)1096-9896(199709)183:1<62::AID-PATH1095>3.0.CO

[105]

2-A

[106]

Peter J, 2001, CANCER RES, V61, P957

[107] Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments [J].

Pittock, SJ ;

Lucchinetti, CF ;

Lennon, VA .

ANNALS OF NEUROLOGY, 2003, 53 (05) :580-587

[108]

PORTER JR, 1994, J UROL S, V264, pA239

[109]

Rai A.J., 2001, Laboratoriums Medizin, V25, P399

[110] Molecular mechanisms of glioma invasiveness: The role of proteases [J].

Rao, JS .

NATURE REVIEWS CANCER, 2003, 3 (07) :489-501

← 6 7 8 9 10 11 12 13 14 15 →